| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8651030 | American Heart Journal | 2018 | 9 Pages |
Abstract
The OCEAN trial is a multicenter randomized controlled trial evaluating 2 antithrombotic treatment strategies for patients with risk factors for stroke after apparently successful AF ablation. We hypothesize that rivaroxaban will reduce the occurrence of clinically overt stroke, systemic embolism, and covert stroke when compared with ASA alone.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Atul MD, Andrew C.T. MD, Paulus MD, Gerhard MD, Jeff S. MD, Michael D. MD, Mukul MD, D. George MD, PhD, Jean MD, Vidal MD, PhD, George PhD, Dhiraj MD, Hein MD, PhD, Prashanthan MBBS, PhD, David H. MD,